These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35706149)

  • 1. Bisphosphonate therapy and orthodontics: implications for postmenopausal women.
    Listik E; Giro G; Negrisoli S; Rodrigues IV; Duarte PM; Nahás-Scocate ACR
    J Clin Orthod; 2022 Mar; 56(3):175-182. PubMed ID: 35706149
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is long-term bisphosphonate therapy associated with benefits to the periodontium in postmenopausal women?
    Palomo L; Buencamino-Francisco MC; Carey JJ; Sivanandy M; Thacker H
    Menopause; 2011 Feb; 18(2):164-70. PubMed ID: 20838348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur.
    Zanchetta MB; Diehl M; Buttazzoni M; Galich A; Silveira F; Bogado CE; Zanchetta JR
    J Bone Miner Res; 2014 Apr; 29(4):999-1004. PubMed ID: 24115250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate and estrogen replacement therapy for postmenopausal periodontitis.
    Haimov-Kochman R; Kochman T; Stabholz A; Hochner-Celinkier D
    Isr Med Assoc J; 2004 Mar; 6(3):173-7. PubMed ID: 15055276
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review.
    Fardellone P; Lello S; Cano A; de Sá Moreira E; Watanabe de Oliveira R; Julian GS; Tang B
    Clin Ther; 2019 Aug; 41(8):1576-1588. PubMed ID: 31151814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incomplete atypical femoral fractures after bisphosphonate use in postmenopausal women.
    Canbek U; Akgun U; Soylemez D; Canbek TD; Aydogan NH
    J Orthop Surg (Hong Kong); 2019; 27(3):2309499019875262. PubMed ID: 31547771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate addition to stable hormone replacement therapy increases bone mineral density in postmenopausal women.
    Boulos P; Sebaldt RJ; Goldsmith CH
    J Rheumatol; 2002 May; 29(5):1110-1. PubMed ID: 12022339
    [No Abstract]   [Full Text] [Related]  

  • 9. Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis.
    Marini F; Falchetti A; Silvestri S; Bagger Y; Luzi E; Tanini A; Christiansen C; Brandi ML
    Curr Med Res Opin; 2008 Sep; 24(9):2609-15. PubMed ID: 18687167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis.
    Meinen R; Galli-Lysak I; Villiger PM; Aeberli D
    BMC Musculoskelet Disord; 2016 Aug; 17():324. PubMed ID: 27491286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is treatment of early postmenopausal women with bisphosphonates justified?
    Epstein S
    Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in trabecular microarchitecture in postmenopausal women on bisphosphonate therapy.
    Greenspan SL; Perera S; Recker R; Wagner JM; Greeley P; Gomberg BR; Seaman P; Kleerekoper M
    Bone; 2010 Apr; 46(4):1006-10. PubMed ID: 20051275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate use for osteoporosis in postmenopausal women may inhibit occurrence of malignant microcalcification in breast tissue.
    Altundag K; Silay YS; Altundag O; Atik MA; Aktolga S
    Med Hypotheses; 2006; 67(1):202-3. PubMed ID: 16165306
    [No Abstract]   [Full Text] [Related]  

  • 14. Bisphosphonate therapy in primary hyperparathyroidism.
    Hershman JM; Hassani S; Braunstein GD; Geola F; Brickman A; Seibel MJ
    J Bone Miner Res; 2003 Oct; 18(10):1889; author reply 1890. PubMed ID: 14584900
    [No Abstract]   [Full Text] [Related]  

  • 15. Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy.
    Ortego-Jurado M; Ríos-Fernández R; Callejas-Rubio JL; Gonzalez-Gay MA; Ortego-Centeno N
    Osteoporos Int; 2014 Aug; 25(8):2157-8. PubMed ID: 24803328
    [No Abstract]   [Full Text] [Related]  

  • 16. Densitometry trends in postmenopausal Asian women undergoing bisphosphonate treatment.
    Ang CL; Singh G; Goh AS; Shen L; Tay BK
    Singapore Med J; 2011 Sep; 52(9):677-80. PubMed ID: 21947146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis.
    Morales-Santana S; Díez-Pérez A; Olmos JM; Nogués X; Sosa M; Díaz-Curiel M; Pérez-Castrillón JL; Pérez-Cano R; Torrijos A; Jodar E; Rio LD; Caeiro-Rey JR; Reyes-García R; García-Fontana B; González-Macías J; Muñoz-Torres M
    Maturitas; 2015 Dec; 82(4):402-10. PubMed ID: 26358930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.
    Miller PD; Pannacciulli N; Malouf-Sierra J; Singer A; Czerwiński E; Bone HG; Wang C; Huang S; Chines A; Lems W; Brown JP
    Osteoporos Int; 2020 Jan; 31(1):181-191. PubMed ID: 31776637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.